4DMedical is establishing a strategic reseller partnership with Azra AI that aims to advance health systems’ ability to manage lung health as a coordinated service line rather than a set of disconnected point solutions.
Azra’s namesake AI-based patient identification platform reviews radiology reports to surface patients whose reports indicate a pulmonary nodule or other incidental finding, often before they have been manually reviewed, according to the Tennessee-based company.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
4DMedical’s imaging solutions span lung health analysis tools for pathologies including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILS) and pulmonary nodules. Meanwhile, the company’s US Food and Drug Administration (FDA)-cleared CT/VQ software turns standard, non-contrast chest CT scans into quantitative lung air and blood flow maps without the need for injected contrast agents or radioactive isotopes.
Under the pair-up, 4DMedical will resell Azra’s enterprise-wide platform to its health system customers, with its own imaging solutions set to be integrated with Azra’s AI tools for “even greater patient discovery” and to provide “objective, measurable data” to guide the next stages of care, the companies stated.
4DMedical’s CEO, Andreas Fouras, commented: “Too often, patients with significant lung disease remain unidentified, or the full extent of their condition is not understood until much later in the care pathway.
“This partnership combines Azra AI’s enterprise-wide patient identification capabilities with 4DMedical’s quantitative imaging and CT:VQ technology, bringing functional lung assessment into the workup earlier. The result is a more informed approach to identifying the right patients, guiding treatment decisions, and managing patients throughout their care journey.”
Once the integration completes, the companies said their combined offerings will result in a consolidated offering. Under this combined workflow, radiology reports will be reviewed, and once relevant findings are surfaced, patients will be routed “automatically and with full clinical context” to the most relevant healthcare professional (HCP).
Reflecting further on the partnership, Azra AI’s CEO, John Marshall, said: “Azra AI is the end-to-end platform that coordinates a patient’s journey from first suspicion to treatment. 4DMedical brings the quantitative lung imaging that turns a finding into a measurable picture of what is happening in patients’ lungs.”
AI is having a significant impact across healthcare, with an outsized impact on the medical imaging space. A report by GlobalData forecasts that AI in healthcare will reach a valuation of $57.4bn in 2029. Looking at the FDA’s list of AI-based medical devices approved in 2026, the overwhelming majority are products designed for applications in the medical imaging space.
